Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.

ABSTRACT: The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug-resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAFi in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the activation of the SRC pathway and promotes the acquisition of an invasive and aggressive resistant phenotype to front-line BRAF inhibitor treatment in melanoma. This nongenetic reprogramming identifies a clinically-compatible approach to reverse BRAFi resistance in melanoma. Using a preclinical BRAFi resistant PDX melanoma model, we demonstrate that SRC inhibition with dasatinib significantly re-sensitizes melanoma cells to BRAFi. Together we identify the AhR/SRC axis as a new therapeutic vulnerability to trigger resistance and warrant the introduction of SRC inhibitors during the course of the treatment in combination with front-line therapeutics to delay BRAFi-resistance.

SUBMITTER: Anais Paris

PROVIDER: S-SCDT-10_15252-EMMM_202215677 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma

Project description:The use of BRAF inhibitors, specific of the BRAFV600E mutation, as a therapeutic strategy for melanoma has significantly improved patient survival. However, resistance mechanisms appear systematically and limit the benefit of treatment. Here we show that AhR transcription factor participates in BRAFi resistance and is associated with the acquisition of an invasive and a dedifferentiated melanoma phenotype by controlling the expression of specific genes. AhR also induces the activation of the c-Src pathway through its phosphorylation, associated with BRAFi resistance. The use of a specific inhibitor of c-Src such as Dasatinib makes it possible to sensitize resistant cells to BRAFi and to prevent the acquisition of an invasive melanoma phenotype by regulating the expression of the AhR-dependent genes.

2022-10-18 | GSE166617 | GEO

An acquired vulnerability of drug resistant melanoma with therapeutic potential

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-04-18 | GSE111141 | GEO

An acquired vulnerability of drug resistant melanoma with therapeutic potential

Project description:An acquired vulnerability of drug resistant melanoma with therapeutic potential

| PRJNA436000 | ENA

MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.

Project description: Not available

| S-EPMC6522293 | biostudies-literature

Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.

Project description: Not available

| S-EPMC5709617 | biostudies-literature

MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma

Project description:Histone modifications, largely regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs) have been recognized as major regulatory mechanisms governing human diseases including cancer. Despite significant effort and recent advances, the mechanism by which the p300 transcriptional coactivator mediates tumorigenesis remains unclear. Here, we use a genetic and chemical approach to identify the Microphthalmia-associated transcription factor (MITF) as a critical downstream target of p300 driving human melanoma growth. We find that direct transcriptional control of MITF by p300-dependent histone acetylation within proximal gene regulatory regions is coupled to cellular proliferation, suggesting a significant growth regulatory axis. Further analysis revealed Forkhead Box M1 (FOXM1) as a key effector of the p300-MITF axis driving cell growth, which is selectively activated in human melanomas. Targeted chemical inhibition of p300 histone acetyltransferase activity using a potent and selective catalytic p300/CBP inhibitor confirmed the critical role of the p300-MITF-FOXM1 axis in melanoma and demonstrated significant growth inhibitory effects in melanoma cells expressing high levels of MITF. These data support p300 as a promising novel epigenetic therapeutic target in human melanoma.

2020-03-22 | GSE128737 | GEO

The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.

Project description: Not available

| S-EPMC7312468 | biostudies-literature

Targeting Electron Transport Chain Confers Therapeutic Vulnerability in Castration-Resistant Prostate Cancer

Project description:Most prostate cancer will develop into castration-resistant prostate cancer, which is the most frequent cause of death for prostate cancer patients. Despite novel androgen receptor antagonists have significantly improved clinical outcomes for these patients, some patients still could not benefit from existing treatment regimens. By analyzing the single-cell RNA-sequencing data and bulk-sequencing data, we discovered that oxidative phosphorylation and electron transport chain (ETC) pathway were enhanced in the prostate cancer microenvironment following tumor progression. Meanwhile, high ETC was related to poor clinical outcomes in prostate cancer patients. Both in vitro and in vivo castration-resistant prostate cancer models demonstrated that ETC inhibitor marked suppressed tumor growth and the synergistic antitumor efficacy of the combination of ETC inhibitor and androgen receptor antagonist. Our study indicates that ETC activity is a metabolic vulnerability for advanced prostate cancer and can serve as a novel therapeutic target.

2023-01-15 | GSE206962 | GEO

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Project description: Not available

| S-EPMC3303496 | biostudies-literature

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.

Project description: Not available

| S-EPMC6010995 | biostudies-literature